Business context and reporting period
This is Sunshine Heart, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015; the filing does not identify the registrant as Nuwellis, Inc. Sunshine Heart was an early-stage medical-device company developing the C-Pulse System for heart failure. The device was not approved for commercial sale in the United States; activity centered on clinical studies and product development.
Financial results and liquidity
Amounts below are in U.S. dollars; income statement and cash-flow figures are for the three months ended March 31. Balance-sheet figures are as of the stated dates.
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Net sales | $59,000 | $59,000 |
| SG&A expense | $2.186 million | $2.361 million; down 7.4% |
| Research and development expense | $4.865 million | $4.063 million; up 19.7% |
| Operating loss | $(6.992) million | $(6.365) million |
| Net loss | $(7.063) million | $(6.332) million |
| Basic and diluted loss per share | $(0.40) | $(0.38) |
| Net cash used in operating activities | $(7.084) million | $(6.687) million |
| Cash and cash equivalents | $37.027 million at March 31, 2015 | $31.293 million at December 31, 2014 |
| Debt | $5.748 million carrying value: $705,000 current and $5.043 million long-term, net of discount | No debt reported at December 31, 2014 |
Gross profit and gross margin are not separately presented. The company reported total assets of $38.795 million, total liabilities of $8.722 million, and stockholders’ equity of $30.073 million at March 31. Cash increased by $5.734 million during the quarter, primarily reflecting $6.902 million of net ATM equity proceeds and $6.0 million in loan proceeds, partly offset by operating and investing cash use. There was $32.8 million of remaining capacity under the ATM sales agreement.
Material changes versus the prior comparable period
- Revenue was unchanged at $59,000, representing one C-Pulse implant in each period; management expected revenue to remain minimal pending clinical-study enrollment and European reimbursement progress.
- R&D spending increased $802,000, primarily for personnel and clinical infrastructure in North America and Europe and development of a fully implantable system. SG&A fell $175,000, attributed to consolidation of certain positions.
- Net loss widened by $731,000. Other expense shifted to $66,000 from $33,000 of other income, primarily because of interest expense on the new SVB borrowing.
- Operating cash use rose by $397,000 year over year. Financing cash inflow increased substantially from $16,000 to $12.902 million, comprising ATM proceeds and debt funding.
- Common shares issued and outstanding increased to 18,233,185 from 16,982,642 at year-end, reflecting the quarter’s ATM sales.
Outlook, risks, and unusual items
- Clinical and regulatory: The FDA had accepted an interim analysis of the COUNTER HF pivotal trial, which could shorten the trial. Enrollment was temporarily paused at a protocol-defined point in March. Following FDA-requested minor protocol changes, the company submitted revisions on April 22, 2015 and was awaiting clearance to resume enrollment.
- Management outlook: R&D expense was expected to remain above prior-year levels throughout 2015 as the company added clinical-study personnel and pursued development efforts. Management expected minimal revenue until U.S. pivotal-study enrollment increased and reimbursement was established in select European markets.
- Funding and going concern: The company reported recurring operating losses and cash outflows, an accumulated deficit of $133.7 million, and expected losses for the foreseeable future. Continuation as a going concern depended on raising additional capital and successful development and commercialization; management cautioned that financing might not be available when needed and that failure could prevent continued operations.
- Debt terms: The February 2015 SVB facility provided up to $10.0 million at 7% annual interest. The company received $6.0 million, with further $2.0 million tranches conditional on FDA acceptance of the interim-analysis plan and enrollment of the 100th COUNTER HF patient by September 30, 2015. Interest-only payments run through January 1, 2016, after which 24 monthly installments are due. The loan is secured by company assets, subject to stated exclusions, includes covenants and a final payment equal to 5% of original principal, and was accompanied by 68,996 ten-year warrants at $5.22 per share.
- Other disclosures: No material legal proceedings, material capital expenditure commitments, or off-balance-sheet arrangements were reported. Management said there were no material changes to the risk factors in its 2014 Form 10-K. Disclosure controls were assessed as effective at a reasonable assurance level.
Important facts for investors to verify
- Confirm the filing identity and issuer: the document is for Sunshine Heart, Inc., despite the request metadata naming Nuwellis, Inc.
- Check subsequent FDA action on the COUNTER HF protocol, timing of trial resumption, interim analysis, and patient enrollment milestones tied to additional loan funding.
- Assess cash use against available liquidity, remaining ATM capacity, debt service obligations, and the company’s stated dependence on future capital raises.
- Review the full loan agreement and warrant terms, including collateral, covenants, contingent tranches, and the final payment.
- Evaluate clinical outcomes, regulatory approval prospects, reimbursement access, and the assumptions underlying the company’s commercialization plans.